For the study, researchers used mouse models to examine bites from the Aedes aegypti mosquito — the primary culprit in the recent outbreak of Zika in the Western Hemisphere. When a mosquito bites, the insect injects saliva into the skin, which then incites a response from the immune system. White blood cells rush to the location of the bite, but instead of combating potential infections, some of the cells become infected and begin inadvertently replicating the virus, helping the infection to spread. When researchers infected mice with Zika sans mosquito bite, the virus failed to replicate as well.
Clive McKimmie, PhD, a research fellow at the University of Leeds in the United Kingdom and senior author of the study, said, “We now want to look at whether medications such as anti-inflammatory creams can stop the virus establishing an infection if used quickly enough after the bite inflammation appears.”
More articles on the Zika virus:
10,000 pregnant women to be enrolled in multinational Zika study
Hundreds of infants in Puerto Rico could be born with Zika-related birth defects, says CDC
Hologic’s diagnostic assay for Zika earns emergency use clearance from FDA
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
